AxoGen AXGN 深 沪
已收盘 08-08 16:00:00 美东时间
13.90
-0.170
-1.21%
华盛通- 最 高14.4899
- 今 开14.12
- 成交量 106.09万股
- 最 低 13.79
- 昨 收 14.07
- 总市值 6.33亿
- 52周最高 21.00
- 市盈率 静 --
- 换手率 2.33%
- 52周最低 9.215
- 委 比 -9.62%
- 总股本 4554.40万
- 历史最高 56.85
- 量 比 0.39
- 振 幅 4.97%
- 历史最低 1.10
- 每 手 1
- 风险率 2.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Axogen shares are trading higher after the company reported better-than-expected Q2 financial results.
Axogen shares are trading higher after the company reported better-than-expecte...
08-05 20:30
Axogen Narrows FY2025 Sales Guidance from $215.439M-$219.185M to $219.000M vs $216.463M Est
Axogen (NASDAQ:AXGN) narrows FY2025 sales outlook from $215.439 million-$219.185 million to $219.000 million vs $216.463 million estimate.
08-05 19:04
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Axogen gains on report of takeover interest
Axogen (NASDAQ:AXGN) rose 3.8% after a report that the company is exploring a possible sale after receiving takeover interest. The company received interest from a strategic buyer for $18 a share, acc...
07-30 01:29
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in peripheral nerve regeneration technologies, announced that its management will host one-on-one investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. Axogen specializes in innovative surgical solutions to restore peripheral nerve function and improve patients' quality of life. Their product portfolio includes advanced nerve repair technologies like Avance Nerve ...
07-29 20:10
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
Axogen Inc. (NASDAQ: AXGN), a leader in peripheral nerve repair solutions, announced it will release its 2025 second-quarter financial results on August 5, 2025. A conference call and webcast will follow at 8 a.m. ET. Investors can join via phone or webcast from Axogen's website. A replay will be available afterward. Axogen specializes in developing innovative technologies to restore peripheral nerve function, offering a comprehensive portfolio o...
07-22 20:05
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
Axogen, Inc. (NASDAQ: AXGN), a global leader in peripheral nerve injury solutions, announced that CEO Michael Dale will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 11, 2025. Axogen develops innovative products like Avance Nerve Graft® and Axoguard Nerve Protector® for nerve repair, addressing both scheduled and emergent surgical needs. The company serves patients in the U.S., Canada, the U.K., South Ko...
05-28 12:00
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Canaccord Genuity Maintains Buy on Axogen, Lowers Price Target to $24
Canaccord Genuity analyst Caitlin Cronin maintains Axogen (NASDAQ:AXGN) with a Buy and lowers the price target from $26 to $24.
05-13 21:56
Healthcare stocks that could be poised for a rebound
Health care (NYSEARCA:XLV) is the most oversold global sector, according to BofA. The sector was down 6.3% from its 200-day moving average in U.S. dollar terms, followed by energy (XLE) and biotechnol...
05-10 00:31
